371 related articles for article (PubMed ID: 28753869)
21. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
22. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
[TBL] [Abstract][Full Text] [Related]
23. Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.
Bismar TA; Hegazy S; Feng Z; Yu D; Donnelly B; Palanisamy N; Trock BJ
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2117-2125. PubMed ID: 30101374
[TBL] [Abstract][Full Text] [Related]
24. Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling.
Shah RB; Bentley J; Jeffery Z; DeMarzo AM
Hum Pathol; 2015 May; 46(5):698-706. PubMed ID: 25724568
[TBL] [Abstract][Full Text] [Related]
25. PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.
Lotan TL; Wei W; Morais CL; Hawley ST; Fazli L; Hurtado-Coll A; Troyer D; McKenney JK; Simko J; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Feng Z; Brooks JD
Eur Urol Focus; 2016 Jun; 2(2):180-188. PubMed ID: 27617307
[TBL] [Abstract][Full Text] [Related]
26. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
[TBL] [Abstract][Full Text] [Related]
27. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
[TBL] [Abstract][Full Text] [Related]
28. 5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors.
Kristensen G; Strand SH; Røder MA; Berg KD; Toft BG; Høyer S; Borre M; Sørensen KD; Brasso K
Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30818754
[TBL] [Abstract][Full Text] [Related]
29. ERG overexpression and multifocality predict prostate cancer in subsequent biopsy for patients with high-grade prostatic intraepithelial neoplasia.
Shah RB; Li J; Dhanani N; Mendrinos S
Urol Oncol; 2016 Mar; 34(3):120.e1-7. PubMed ID: 26585946
[TBL] [Abstract][Full Text] [Related]
30. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).
El Hajj A; Ploussard G; de la Taille A; Allory Y; Vordos D; Hoznek A; Abbou CC; Salomon L
BJU Int; 2013 Jan; 111(1):53-9. PubMed ID: 22726582
[TBL] [Abstract][Full Text] [Related]
31. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
[TBL] [Abstract][Full Text] [Related]
32. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
[TBL] [Abstract][Full Text] [Related]
33. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
Huang KC; Evans A; Donnelly B; Bismar TA
Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
[TBL] [Abstract][Full Text] [Related]
34. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
35. Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers.
Wang X; Qi M; Zhang J; Sun X; Guo H; Pang Y; Zhang Q; Chen X; Zhang R; Liu Z; Liu L; Hao X; Han B
Prostate; 2019 May; 79(7):709-719. PubMed ID: 30825345
[TBL] [Abstract][Full Text] [Related]
36. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
[TBL] [Abstract][Full Text] [Related]
37. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
[TBL] [Abstract][Full Text] [Related]
38. PTEN and ERG detection in multiparametric magnetic resonance imaging/ultrasound fusion targeted prostate biopsy compared to systematic biopsy.
Baumgartner E; Del Carmen Rodriguez Pena M; Eich ML; Porter KK; Nix JW; Rais-Bahrami S; Gordetsky J
Hum Pathol; 2019 Aug; 90():20-26. PubMed ID: 31075299
[TBL] [Abstract][Full Text] [Related]
39. PIN-like (Ductal) Adenocarcinoma of the Prostate.
Paulk A; Giannico G; Epstein JI
Am J Surg Pathol; 2018 Dec; 42(12):1693-1700. PubMed ID: 30138215
[TBL] [Abstract][Full Text] [Related]
40. Prognostic features of Annexin A2 expression in prostate cancer.
Tan SH; Young D; Chen Y; Kuo HC; Srinivasan A; Dobi A; Petrovics G; Cullen J; Mcleod DG; Rosner IL; Srivastava S; Sesterhenn IA
Pathology; 2021 Feb; 53(2):205-213. PubMed ID: 32967771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
